A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice.
Antimicrobial treatment strategies must improve to reduce the high mortality rates in septic patients. In noninfectious models of acute inflammation, activation of A2B adenosine receptors (A2BR) in extracellular adenosine-rich microenvironments causes immunosuppression. We examined A2BR in antibacterial responses in the cecal ligation and puncture (CLP) model of sepsis. Antagonism of A2BR significantly increased survival, enhanced bacterial phagocytosis, and decreased IL-6 and MIP-2 (a CXC chemokine) levels after CLP in outbred (ICR/CD-1) mice. During the CLP-induced septic response in A2BR knockout mice, hemodynamic parameters were improved compared with wild-type mice in addition to better survival and decreased plasma IL-6 levels. A2BR deficiency resulted in a dramatic 4-log reduction in peritoneal bacteria. The mechanism of these improvements was due to enhanced macrophage phagocytic activity without augmenting neutrophil phagocytosis of bacteria. Following ex vivo LPS stimulation, septic macrophages from A2BR knockout mice had increased IL-6 and TNF-α secretion compared with wild-type mice. A therapeutic intervention with A2BR blockade was studied by using a plasma biomarker to direct therapy to those mice predicted to die. Pharmacological blockade of A2BR even 32 h after the onset of sepsis increased survival by 65% in those mice predicted to die. Thus, even the late treatment with an A2BR antagonist significantly improved survival of mice (ICR/CD-1) that were otherwise determined to die according to plasma IL-6 levels. Our findings of enhanced bacterial clearance and host survival suggest that antagonism of A2BRs offers a therapeutic target to improve macrophage function in a late treatment protocol that improves sepsis survival.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.
Bryan G
BG
Belikoff
Stephen
S
Hatfield
Peter
P
Georgiev
Akio
A
Ohta
Dmitriy
D
Lukashev
Jon A
JA
Buras
Daniel G
DG
Remick
Michail
M
Sitkovsky
D000818:Animals; D018949:Antigens, CD1 / Q000096:biosynthesis; D002432:Cecum; D005260:Female; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D015850:Interleukin-6 / Q000378:metabolism; D008026:Ligation; D008264:Macrophages / Q000276:immunology* / Q000382:microbiology / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D018345:Mice, Knockout; D008822:Mice, Transgenic; D010587:Phagocytosis / Q000235:genetics / Q000276:immunology*; D011677:Punctures; D043704:Receptor, Adenosine A2B / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D018805:Sepsis / Q000235:genetics / Q000276:immunology* / Q000401:mortality; D015996:Survival Rate; D015854:Up-Regulation / Q000235:genetics / Q000276:immunology*; D000093242:Interleukin-6 Inhibitors
D018949:Antigens, CD1; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D043704:Receptor, Adenosine A2B; D000093242:Interleukin-6 Inhibitors
Shock. 1998 Aug;10(2):110-7
9721977
Crit Care Med. 2001 Apr;29(4):765-9
11373466
Blood. 2004 Dec 15;104(13):3986-92
15319286
J Exp Med. 2009 Aug 31;206(9):1883-97
19652016
J Cell Mol Med. 2009 Oct;13(10):4154-60
19725914
N Engl J Med. 2009 Oct 15;361(16):1570-83
19828534
Crit Care Med. 2004 Nov;32(11):2207-18
15640632
Clin Immunol Immunopathol. 1987 Jan;42(1):76-85
3024892
Am J Pathol. 2007 May;170(5):1435-44
17456750
J Clin Invest. 2006 Jul;116(7):1913-23
16823489
Infect Immun. 2006 Sep;74(9):5227-35
16926416
Shock. 2004 Jan;21(1):17-25
14676679
Crit Care Med. 2007 May;35(5):1244-50
17414736
J Exp Med. 2009 Oct 26;206(11):2417-27
19808256
J Immunol. 2007 Jul 1;179(1):623-30
17579084
Pharmacol Rev. 2001 Dec;53(4):527-52
11734617
J Exp Med. 2006 Jun 12;203(6):1447-58
16702604
Expert Opin Biol Ther. 2001 May;1(3):343-57
11727510
Crit Care Med. 2001 Jul;29(7):1303-10
11445675
J Clin Invest. 1991 Nov;88(5):1747-54
1939659
Nat Immunol. 2009 Feb;10(2):195-202
19122655
J Immunol. 2007 Jul 15;179(2):1254-63
17617618
Nat Rev Drug Discov. 2003 May;2(5):391-405
12750742
FASEB J. 2006 Nov;20(13):2242-50
17077301
Nature. 1996 May 2;381(6577):75-7
8609992
J Immunol. 2010 Jul 1;185(1):542-50
20505145
J Med Chem. 2002 May 23;45(11):2131-8
12014951
Nature. 2001 Dec 20-27;414(6866):916-20
11780065
J Immunol. 2005 Apr 15;174(8):5040-6
15814735
Shock. 2004 Feb;21(2):121-5
14752284
Trends Immunol. 2009 Jun;30(6):263-70
19427267
PLoS Biol. 2005 Jun;3(6):e174
15857155
Science. 2006 Dec 15;314(5806):1792-5
17170310
PLoS Med. 2008 Jun 24;5(6):e137
18578565
J Clin Invest. 2006 Jul;116(7):1835-7
16823484
J Clin Invest. 2008 Oct;118(10):3301-15
18787641
Shock. 1996;6 Suppl 1:S27-38
8828095
Nature. 1988 Sep 8;335(6186):176-8
3412473
Nat Rev Drug Discov. 2005 Oct;4(10):854-65
16224456
J Immunol. 2008 Jun 1;180(11):7212-20
18490720
J Immunol. 2006 May 1;176(9):5616-26
16622031
Chest. 2004 Jun;125(6):2206-16
15189943
Annu Rev Immunol. 2004;22:657-82
15032592
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6303-8
19332785
Biochem Biophys Res Commun. 2008 Oct 24;375(3):292-6
18647598
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):792-6
18184815
Nat Rev Drug Discov. 2008 Sep;7(9):759-70
18758473
Crit Care Med. 2003 Aug;31(8):2228-37
12973184
Crit Care Med. 2009 May;37(5):1567-73
19325479